The overlooked biochemical pathway: how insulin resistance (HOMA-IR) modulates metabolic masking of prostate-specific antigen separately from body mass index
| dc.contributor.author | Eren, Murat Tugrul | |
| dc.contributor.author | Ozveri, Hakan | |
| dc.date.accessioned | 2026-11-05T11:00:33Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background Conventional prostate cancer screening profiles rely heavily on static serum prostate-specific antigen (PSA) thresholds, consistently overlooking the confounding impacts of the modern metabolic syndrome epidemic. This study aimed to isolate and quantify the long-term longitudinal impact of insulin resistance (HOMA-IR) and Body Mass Index (BMI) on serum PSA levels. Materials and methods We retrospectively evaluated 9095 routine annual screening records from 5,846 asymptomatic male subjects (2016-2026) with concurrent clinical data for PSA, HOMA-IR, BMI, and total testosterone. Linear Mixed-Effects Models with subject-specific random intercepts were constructed to rigorously account for intra-subject correlations across consecutive annual follow-up visits. Results Multi-variable longitudinal analysis demonstrated that while BMI exhibited a strong downward trend on baseline biomarkers (per-unit decrease of 0.018 ng/mL (p = 0.057), elevated HOMA-IR served as a statistically significant, independent biochemical marker inversely associated with serum PSA (p = 0.042). Crucially, categorical stratification revealed a highly significant, non-linear biomarker collapse: subjects in the highest cumulative metabolic burden quadrant (concurrent BMI >= 35 kg/m(2) and HOMA-IR > 3.0) exhibited a profound 34.8% reduction in age-adjusted serum PSA concentrations compared to metabolically healthy, normal-weight counterparts (p < 0.001). Conclusions Metabolic masking of serum PSA is a complex, two-pronged process characterized by physical hemodilution via tissue mass and cellular transcription-level suppression via chronic hyperinsulinemia. Transitioning away from simplistic weight-based corrections in clinical preventive screening guidelines along with systematic integration of insulin resistance profiles into individualized urological risk stratification may help eliminate this critical diagnostic blind spot. | |
| dc.identifier.doi | 10.1007/s11255-026-05304-z | |
| dc.identifier.issn | 0301-1623 | |
| dc.identifier.issn | 1573-2584 | |
| dc.identifier.uri | https://doi.org/10.1007/s11255-026-05304-z | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/10479 | |
| dc.identifier.wos | WOS:001848267100001 | |
| dc.language.iso | en | |
| dc.publisher | SPRINGER | |
| dc.relation.hasversion | 10.1007/s11255-026-05304-z | |
| dc.relation.ispartof | INTERNATIONAL UROLOGY AND NEPHROLOGY | |
| dc.subject | Prostate-specific antigen | |
| dc.subject | Insulin resistance | |
| dc.subject | HOMA-IR | |
| dc.subject | Metabolic masking | |
| dc.subject | Body mass index | |
| dc.subject | Biomarkers | |
| dc.subject | OBESITY | |
| dc.subject | Urology & Nephrology | |
| dc.title | The overlooked biochemical pathway: how insulin resistance (HOMA-IR) modulates metabolic masking of prostate-specific antigen separately from body mass index | |
| dc.type | Article | |
| oaire.citation.edition | Science Citation Index Expanded (SCI-EXPANDED) | |
| person.identifier.rid | PDX-3027-2025 |
